Vora Robin A, Patel Amar P, Yang Sam S, Melles Ronald
Kaiser Permanente Northern California, 275 W. MacArthur Blvd, Oakland, CA, 94612, USA.
Am J Ophthalmol Case Rep. 2020 Jan 25;17:100604. doi: 10.1016/j.ajoc.2020.100604. eCollection 2020 Mar.
To describe a patient with a past diagnosis of Stargardt disease that was later determined to be pentosan polysulfate (PPS) maculopathy.
The patient had clinical and imaging findings uncharacteristic of Stargardt disease. Rather, her fundus resembled the recently described maculopathy ascribed to PPS. After genetic testing was found to be negative for pathologic variants, the patient was asked to cease usage of PPS.
This case emphasizes the importance of reviewing patient medication profiles prior to rendering a diagnosis of a retinal dystrophy. It is essential that ophthalmologists catch drug toxicities as early as possible, to minimize risk of further irreversible vision loss due to continued medication exposure.
描述一名既往诊断为斯塔加特病的患者，该患者后来被确定患有戊聚糖多硫酸盐（PPS）黄斑病变。
该患者具有不符合斯塔加特病特征的临床和影像学表现。相反，她的眼底类似于最近描述的归因于PPS的黄斑病变。在基因检测发现病理性变异呈阴性后，要求患者停止使用PPS。
该病例强调了在诊断视网膜营养不良之前审查患者用药情况的重要性。眼科医生尽早发现药物毒性至关重要，以尽量减少因持续接触药物导致进一步不可逆视力丧失的风险。
